CMS Reconsiders PET Scan NCD In Preparation For Alzheimer’s mAbs Trials

By John Wilkerson / June 23, 2022 at 4:50 PM
CMS is considering loosening Medicare coverage restrictions of positron emission tomography (PET) imaging for amyloid beta plaques in response to public comments it received on the national coverage policy for the Alzheimer’s drug Aduhelm. CMS covers one PET scan per patient and policy makers said clinical trial protocols for Aduhelm might require more than one scan. “The purpose of this NCD reconsideration is to determine if the current policy of one scan per patient per lifetime should be revised,” CMS...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.